Ibrance(palbociclib)
Ibrance (palbociclib) is a small molecule pharmaceutical. Palbociclib was first approved as Ibrance on 2015-02-03. It is used to treat breast neoplasms in the USA. It has been approved in Europe to treat breast neoplasms. The pharmaceutical is active against cyclin-dependent kinase 4 and cyclin-dependent kinase 6.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Trade Name
FDA
EMA
Ibrance
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ibrance | New Drug Application | 2022-11-30 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| breast neoplasms | EFO_0003869 | D001943 | C50 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
299 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 50 | 85 | 19 | 4 | 26 | 165 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 12 | 16 | 1 | — | 2 | 27 | |
| Triple negative breast neoplasms | D064726 | 3 | 6 | 2 | — | — | 9 | ||
| Male breast neoplasms | D018567 | 2 | 3 | 3 | — | 1 | 9 | ||
| Sarcoma | D012509 | 2 | 5 | 1 | — | — | 8 | ||
| Squamous cell carcinoma of head and neck | D000077195 | 2 | 5 | 1 | — | — | 7 | ||
| Squamous cell neoplasms | D018307 | 1 | 2 | 1 | — | 1 | 4 | ||
| Squamous cell carcinoma | D002294 | — | 1 | 1 | — | 1 | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | 6 | 8 | — | — | — | 10 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 5 | 3 | — | — | — | 8 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | 6 | — | — | — | 8 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 7 | 1 | — | — | — | 7 | |
| Non-hodgkin lymphoma | D008228 | C85.9 | 2 | 4 | — | — | — | 6 | |
| Multiple myeloma | D009101 | C90.0 | 2 | 4 | — | — | — | 6 | |
| Colorectal neoplasms | D015179 | 3 | 4 | — | — | — | 6 | ||
| Melanoma | D008545 | 2 | 5 | — | — | — | 5 | ||
| Head and neck neoplasms | D006258 | 3 | 3 | — | — | — | 5 | ||
| Myeloid leukemia acute | D015470 | C92.0 | 4 | 1 | — | — | — | 4 |
Show 55 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 18 | — | — | — | — | 18 | ||
| Castration-resistant prostatic neoplasms | D064129 | 2 | — | — | — | — | 2 | ||
| Syndrome | D013577 | 2 | — | — | — | — | 2 | ||
| Myelodysplastic syndromes | D009190 | D46 | 1 | — | — | — | — | 1 | |
| Hematologic neoplasms | D019337 | 1 | — | — | — | — | 1 | ||
| Primary myelofibrosis | D055728 | D47.4 | 1 | — | — | — | — | 1 | |
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | 1 | — | — | — | — | 1 | |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | 1 | — | — | — | — | 1 | |
| Myelomonocytic leukemia chronic | D015477 | C93.1 | 1 | — | — | — | — | 1 | |
| Anemia | D000740 | EFO_0004272 | D64.9 | 1 | — | — | — | — | 1 |
Show 20 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Radiotherapy | D011878 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PALBOCICLIB |
| INN | palbociclib |
| Description | Palbociclib is a member of the class of pyridopyrimidines that is 2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7-one bearing additional methyl, acetyl and cyclopentyl substituents at positions 5, 6 and 8 respectively. It is used in combination with letrozole for the treatment of metastatic breast cancer. It has a role as an EC 2.7.11.22 (cyclin-dependent kinase) inhibitor and an antineoplastic agent. It is a pyridopyrimidine, an aminopyridine, a secondary amino compound, a member of piperidines, an aromatic ketone, a member of cyclopentanes and a tertiary amino compound. |
| Classification | Small molecule |
| Drug class | cyclin dependent kinase inhibitors (formerly-cidib) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O |
Identifiers
| PDB | 2EUF |
| CAS-ID | 571190-30-2 |
| RxCUI | 1601374 |
| ChEMBL ID | CHEMBL189963 |
| ChEBI ID | 85993 |
| PubChem CID | 5330286 |
| DrugBank | DB09073 |
| UNII ID | G9ZF61LE7G (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
Ibrance - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,767 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more